Evidence map›Paper›PMID 31375069›Full record

ArticleBMC neurology2019

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA.

Tobias Frühwald, Ulrich Gärtner, Nils Stöckmann, Jan-Henning Marxsen, Carolin Gramsch, Florian C Roessler

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tobias FrühwaldDepartment of Neurology, Justus-Liebig-University Gießen, Klinikstraße 33, 35385, Gießen, Germany.
Ulrich GärtnerInstitute of Anatomy and Cell Biology, Justus-Liebig-University Gießen, Aulweg 123, 35392, Gießen, Germany.
Nils StöckmannDepartment of Neurology, Justus-Liebig-University Gießen, Klinikstraße 33, 35385, Gießen, Germany.
Jan-Henning MarxsenOncology Practice Am Marien-Krankenhaus, Parade 5, 23552, Lübeck, Germany.
Carolin GramschDepartment of Neuroradiology, Justus-Liebig-University Gießen, Klinikstraße 33, 35385, Gießen, Germany.
Florian C RoesslerDepartment of Neurology, Justus-Liebig-University Gießen, Klinikstraße 33, 35385, Gießen, Germany. florian.roessler@neuro.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOptimizing thrombolytic therapy is vital for improving stroke outcomes. We aimed to develop standardized thrombolysis conditions to evaluate the efficacy of tenecteplase (TNK) compared to the current gold standard rt-PA (alteplase), with and without additional ultrasound treatment. We also wanted to introduce a new analytical approach to quantify fibrin fiber density in transmission electron microscopy (TEM).

methodsIn vitro clots that are similar to ex vivo clots concerning their histological condition and their durability were generated from whole blood. For five treatment groups we compared relative clot weight loss (each n = 60) and fibrin fiber density in TEM (each n = 5). The control group (A) was treated only with plasma. Two groups were designated for each rt-PA (B + C) and TNK (D + E). Groups C and E were additionally treated with ultrasound. Dosages were 50 μg/ml for rt-PA and 30 μg/ml for TNK. Results were evaluated by using analyses of variance (ANOVA) and post-hoc t-tests.

resultsWeight loss was increased significantly for all groups compared to the control group. Both TNK groups showed significantly increased weight loss compared to their counterpart rt-PA group (p ≤ 0.001). For TEM only group D showed significantly decreased fibrin fiber density (p < 0.05) compared to both rt-PA groups. Ultrasound did not significantly increase dissolution of clots with either method (best p = 0.16).

conclusionsTenecteplase dissolved clots more effectively than rt-PA with and without ultrasound. A higher sample size could provide more convincing results for TEM.

Indexed as

Ultrasonic TherapyDrug Evaluation, PreclinicalFibrinolytic AgentsHumansStrokeTenecteplaseThrombolytic TherapyThrombosisTissue Plasminogen ActivatorFibrinolytic AgentsTenecteplaseTissue Plasminogen ActivatorStrokeTenecteplaseThrombolysisTransmission electron microscopyUltrasound

Identifiers

PMID31375069
PMCPMC6676584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.